Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) Shares Acquired by State Street Corp

State Street Corp boosted its position in shares of Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) by 6.8% in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 2,471,215 shares of the biopharmaceutical company’s stock after purchasing an additional 157,738 shares during the period. State Street Corp owned approximately 1.00% of Lexicon Pharmaceuticals worth $3,880,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. FMR LLC lifted its stake in shares of Lexicon Pharmaceuticals by 28.9% in the third quarter. FMR LLC now owns 49,867,042 shares of the biopharmaceutical company’s stock worth $78,291,000 after acquiring an additional 11,179,919 shares in the last quarter. Point72 Asset Management L.P. increased its holdings in shares of Lexicon Pharmaceuticals by 605.2% in the 2nd quarter. Point72 Asset Management L.P. now owns 4,121,191 shares of the biopharmaceutical company’s stock valued at $6,924,000 after acquiring an additional 3,536,805 shares during the last quarter. Nantahala Capital Management LLC acquired a new position in shares of Lexicon Pharmaceuticals in the 2nd quarter valued at about $3,871,000. Pinnacle Associates Ltd. grew its position in shares of Lexicon Pharmaceuticals by 0.9% during the 3rd quarter. Pinnacle Associates Ltd. now owns 1,730,821 shares of the biopharmaceutical company’s stock valued at $2,648,000 after buying an additional 14,990 shares during the last quarter. Finally, Charles Schwab Investment Management Inc. raised its stake in Lexicon Pharmaceuticals by 4.3% during the third quarter. Charles Schwab Investment Management Inc. now owns 1,417,295 shares of the biopharmaceutical company’s stock worth $2,225,000 after acquiring an additional 58,147 shares during the period. Hedge funds and other institutional investors own 74.70% of the company’s stock.

Lexicon Pharmaceuticals Stock Down 7.0 %

NASDAQ:LXRX opened at $0.72 on Tuesday. The business’s fifty day moving average price is $1.05 and its 200 day moving average price is $1.52. The firm has a market capitalization of $177.19 million, a price-to-earnings ratio of -0.96 and a beta of 1.07. The company has a current ratio of 7.45, a quick ratio of 7.43 and a debt-to-equity ratio of 0.56. Lexicon Pharmaceuticals, Inc. has a 1-year low of $0.62 and a 1-year high of $3.73.

Lexicon Pharmaceuticals (NASDAQ:LXRX) last posted its quarterly earnings results on Tuesday, November 12th. The biopharmaceutical company reported ($0.18) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.17) by ($0.01). Lexicon Pharmaceuticals had a negative return on equity of 107.38% and a negative net margin of 4,109.41%. The company had revenue of $1.75 million during the quarter, compared to analysts’ expectations of $3.14 million. During the same period last year, the company earned ($0.21) earnings per share. On average, sell-side analysts forecast that Lexicon Pharmaceuticals, Inc. will post -0.66 earnings per share for the current fiscal year.

Analyst Ratings Changes

A number of equities research analysts have issued reports on LXRX shares. Needham & Company LLC reiterated a “hold” rating on shares of Lexicon Pharmaceuticals in a research note on Monday, December 23rd. HC Wainwright restated a “buy” rating and issued a $6.00 target price on shares of Lexicon Pharmaceuticals in a research report on Wednesday, November 13th. Finally, Leerink Partners set a $6.00 price target on Lexicon Pharmaceuticals and gave the company an “outperform” rating in a report on Friday, October 18th. One analyst has rated the stock with a sell rating, one has issued a hold rating and three have issued a buy rating to the company. According to data from MarketBeat, Lexicon Pharmaceuticals currently has a consensus rating of “Hold” and a consensus target price of $6.00.

Lexicon Pharmaceuticals Company Profile

Lexicon Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products. Its orally-delivered small molecule drug candidates under development comprise Sotagliflozin that completed Phase III clinical trials for the for the treatment of heart failure and type 1 diabetes; and LX9211, which is in Phase II clinical development for the treatment of neuropathic pain and LX2761, which is in Phase I clinical development for gastrointestinal tract.